Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GenomedWAR:GEN +4.90%87 EV-to-EBIT is 8.73 as of Aug. 13, 2026, which is 71% below its 10-year median of 29.92. GuruFocus rates WAR:GEN with a GF Score™ of 87/100 and a GF Value™ of zł38.44 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 105 Medical Diagnostics & Research companies, Genomed ranks better than 84.76% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Genomed's Enterprise Value is zł33.54 Mil.
Genomed's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was zł3.84 Mil. Therefore, Genomed's EV-to-EBIT for today is 8.73.
The historical rank and industry rank for Genomed's EV-to-EBIT or its related term are showing as below:
WAR:GEN'
s EV-to-EBIT Range Over the Past 10 Years
Min: -5649.89 Med: 29.92 Max: 265.96
Current: 8.73
During the past 13 years, the highest EV-to-EBIT of Genomed was 265.96. The lowest was -5649.89. And the median was 29.92.
WAR:GEN's EV-to-EBIT is ranked better than 84.76% of 105
companies
in the Medical Diagnostics & Research industry
Industry Median: 24.25
vs WAR:GEN: 8.73
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Genomed's Enterprise Value for the quarter that ended in Mar. 2026 was zł27.76 Mil.
Genomed's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł3.84 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomed EV-to-EBIT Related Terms
Genomed EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Genomed's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Genomed's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomed EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genomed's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Genomed's EV-to-EBIT falls into.
Genomed's current Enterprise Value is zł33.54 Mil.
Genomed's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł3.84 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomed (WAR:GEN) has a EV-to-EBIT of 8.73 as of Aug. 13, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Genomed and its competitors. This is 71% below median its historical median of 29.92. According to the industry distribution chart, Genomed ranks #16 out of 105 companies in the Medical Diagnostics & Research industry, placing it in the top 15.2%.
Is Genomed's EV-to-EBIT too high?
Genomed's current EV-to-EBIT of 8.73 is 71% below median its 10-year median of 29.92. The Medical Diagnostics & Research industry median EV-to-EBIT is 24.25. Genomed's value of 8.73 is 64% below this industry median. Based on the distribution chart, Genomed ranks #16 out of 105 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Genomed has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomed's EV-to-EBIT compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genomed ranks #16 out of 105 companies for EV-to-EBIT. This places Genomed in the top 15% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 24.25. Genomed's value of 8.73 is 64% below this benchmark. While the company's 10-year median is 29.92 vs. the industry median of 24.25, Genomed has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 24.25, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomed's current EV-to-EBIT of 8.73 is 64% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Genomed and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 24.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomed's current EV-to-EBIT is 8.73, which is 71% below median its own 10-year median of 29.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomed stock overvalued right now?
Based on GuruFocus' analysis, Genomed (WAR:GEN) is currently considered Modestly Undervalued. The stock's GF Value™ is zł38.44, compared to a current price of zł30.00 — trading 22% below its estimated fair value. The current EV-to-EBIT is 8.73, which is 71% below median its 10-year median of 29.92 and 64% below the Medical Diagnostics & Research industry median of 24.25. Genomed's overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Genomed (WAR:GEN), the current EV-to-EBIT is 8.73 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomed (WAR:GEN) Overvalued in 2026?
Based on GuruFocus' analysis, Genomed stock appears to be undervalued.
The current stock price of zł30.00 is trading 22% below its estimated GF Value™ of zł38.44.
GuruFocus considers Genomed to be Modestly Undervalued.
Key valuation signals for WAR:GEN:
EV-to-EBIT: 8.73 (71% below median its 10-year median of 29.92)
GF Value™: zł38.44 vs. price of zł30.00 (22% below fair value)
Industry Position: 64% below the Medical Diagnostics & Research median (#16 of 105)
No single metric tells the full story. See the WAR:GEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomed SA assembles outstanding molecular biologists and genetic diagnosticians. The company provides diagnostic service that comprises DNA analysis and congenital diseases diagnostics based on DNA sequencing. It offers Diagnostic service and Service for scientific purposes.
87GF Score
Get the complete analysis for WAR:GEN
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:GEN has been successfully added to your 
